Solvanix Overview
- Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$1.63M
- Investors
-
1
Solvanix General Information
Description
Developer of a novel technology designed to improve stability and reduce the aggregation of fully human antibodies. The company's technology helps to boost stability and reduce aggregation of monoclonal antibodies, antibody fragments, and bi-specifics, enabling biotech and pharma partners to improve therapeutic antibodies.
Contact Information
Website
www.solvanix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
- 384 Victoria Street
- Darlinghurst, New South Wales 2010
- Australia
+61 0000000000
Solvanix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 15-Jan-2015 | $1.63M | 00.000 | Completed | Generating Revenue |
Solvanix Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Daniel Christ Ph.D | Founder & Chief Scientific Officer | ||
| Philip Wallace Ph.D | Head of Product and Business Development |
Solvanix Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christopher Smith Ph.D | Brandon Capital | Board Member | 000 0000 |
| Jenny Harry Ph.D | Self | Board Member | 000 0000 |
Solvanix Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Brandon Capital | Venture Capital | Minority | 000 0000 | 000000 0 |